A Phase 1 Combined Single and Multiple Oral Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ESN364 in Healthy Japanese Male and Pre- and Post-menopausal Female Subjects

Trial Profile

A Phase 1 Combined Single and Multiple Oral Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ESN364 in Healthy Japanese Male and Pre- and Post-menopausal Female Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Jun 2018

At a glance

  • Drugs Fezolinetant (Primary)
  • Indications Hot flashes; Polycystic ovary syndrome; Uterine leiomyoma; Weight gain
  • Focus Adverse reactions
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 05 Jun 2018 Status changed from active, no longer recruiting to completed.
    • 11 May 2018 Status changed from recruiting to active, no longer recruiting.
    • 06 Mar 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top